Advances in ocular drug delivery systems

Kang-Mieler, Jennifer J.; Rudeen, Kayla M; Liu, Wenqiang; Mieler, William F.

doi:10.1038/s41433-020-0809-0

Cited by 87 publications

(82 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Limitations of liposomes include the relatively limited amount of transportable drug that can be encapsulated, the need for caution during sterilization procedures, and the risk of interference with vision (blurring effect) after intravitreal injections [146].…”

Section: Liposomesmentioning

confidence: 99%

Regulation of the Ocular Cell/Tissue Response by Implantable Biomaterials and Drug Delivery Systems

Baino

Kargozar

2020

Bioengineering

View full text Add to dashboard Cite

Therapeutic advancements in the treatment of various ocular diseases is often linked to the development of efficient drug delivery systems (DDSs), which would allow a sustained release while maintaining therapeutic drug levels in the target tissues. In this way, ocular tissue/cell response can be properly modulated and designed in order to produce a therapeutic effect. An ideal ocular DDS should encapsulate and release the appropriate drug concentration to the target tissue (therapeutic but non-toxic level) while preserving drug functionality. Furthermore, a constant release is usually preferred, keeping the initial burst to a minimum. Different materials are used, modified, and combined in order to achieve a sustained drug release in both the anterior and posterior segments of the eye. After giving a picture of the different strategies adopted for ocular drug release, this review article provides an overview of the biomaterials that are used as drug carriers in the eye, including micro- and nanospheres, liposomes, hydrogels, and multi-material implants; the advantages and limitations of these DDSs are discussed in reference to the major ocular applications.

show abstract

Section: Liposomesmentioning

confidence: 99%

Regulation of the Ocular Cell/Tissue Response by Implantable Biomaterials and Drug Delivery Systems

Baino

Kargozar

2020

Bioengineering

View full text Add to dashboard Cite

show abstract

“…The structure of the eye can be split into two main parts, namely, the anterior segment and the posterior segment [ 1 , 2 ]. As shown in Figure 1 , the anterior segment includes the iris, ciliary body, cornea, conjunctiva, aqueous humor and lens, whereas the choroid sclera, neural retina, retinal pigment epithelium, vitreous humor and optic nerve belong to the posterior segment.…”

Section: Introductionmentioning

confidence: 99%

“…The eye offers multiple routes through which ocular drugs can be delivered. Drug delivery to the anterior segment of the eye is currently achieved throughout topical and subconjunctival routes or injected intracamerally [ 2 ]. A topical eye drop is the most convenient and patient compliant route of drug administration, especially for the treatment of anterior segment diseases [ 3 , 4 ].…”

Section: Introductionmentioning

confidence: 99%

“…Bearing in mind the fibrous composition and large surface area, the sclera offers less resistance to drug diffusion. Kang-Mieler’s group has shown that molecules up to 70 kDa can readily penetrate the sclera, whereas only those below 1 kDa penetrate through the cornea [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

“…Different conventional and innovative drug delivery systems, such as ointments, emulsions, aqueous gels, suspensions, nanoparticles, nanomicelles, dendrimers, liposomes, implants, contact lenses, nanosuspensions, microneedles and in situ thermosensitive gels, have been developed with the aim to overcome the ocular barriers and improve drug bioavailability in eye tissues [ 7 ]. Advances in nanotechnology have resulted in the development of ocular formulations based on biodegradable microparticles and nanoparticles, hydrogels and also implants, resulting the improvement of the bioavailability of several ocular drugs [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Nanopharmaceuticals for Eye Administration: Sterilization, Depyrogenation and Clinical Applications

Zielińska

Soles

Lopes

et al. 2020

Biology

View full text Add to dashboard Cite

As an immune-privileged target organ, the eyes have important superficial and internal barriers, protecting them from physical and chemical damage from exogenous and/or endogenous origins that would cause injury to visual acuity or even vision loss. These anatomic, physiological and histologic barriers are thus a challenge for drug access and entry into the eye. Novel therapeutic concepts are highly desirable for eye treatment. The design of an efficient ocular drug delivery system still remains a challenge. Although nanotechnology may offer the ability to detect and treat eye diseases, successful treatment approaches are still in demand. The growing interest in nanopharmaceuticals offers the opportunity to improve ophthalmic treatments. Besides their size, which needs to be critically monitored, nanopharmaceuticals for ophthalmic applications have to be produced under sterilized conditions. In this work, we have revised the different sterilization and depyrogenation methods for ophthalmic nanopharmaceuticals with their merits and drawbacks. The paper also describes clinical sterilization of drugs and the outcomes of inappropriate practices, while recent applications of nanopharmaceuticals for ocular drug delivery are also addressed.

show abstract

Long‐Acting Protective Ocular Surface by Instilling Adhesive Dual‐Antiviral Nanoparticles

Wang

Chen

Wang

et al. 2022

Adv Healthcare Materials

View full text Add to dashboard Cite

The eye is susceptible to viral infections, causing severe ocular symptoms or even respiratory diseases. Methods capable of protecting the eye from external viral invasion in a long‐term and highly effective way are urgently needed but have been proved to be extremely challenging. Here, a strategy of forming a long‐acting protective ocular surface is described by instilling adhesive dual‐antiviral nanoparticles. Taking pseudotyped severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) as a model virus, antiviral agent‐loaded nanoparticles are coated with a “double‐lock” hybrid cell membrane abundant with integrin‐β1 and angiotensin converting enzyme II (ACE2). After instillation, the presence of integrin‐β1 endows coated nanoparticles with steady adhesion via specific binding to Arg‐Gly‐Asp sequence on the fibronectin of ocular epithelium, achieving durable retention on the ocular surface. In addition to loaded inhibitors, the exposure of ACE2 can trap SARS‐CoV‐2 and subsequently neutralize the associated spike protein, playing a dual antiviral effect of the resulting nanoparticles. Adhesive dual‐antiviral nanoparticles enabled by coating with a “double‐lock” hybrid cell membrane could be a versatile platform for topical long‐acting protection against viral infection of the eye.

show abstract

Advances in ocular drug delivery systems

Cited by 87 publications

References 49 publications

Regulation of the Ocular Cell/Tissue Response by Implantable Biomaterials and Drug Delivery Systems

Regulation of the Ocular Cell/Tissue Response by Implantable Biomaterials and Drug Delivery Systems

Nanopharmaceuticals for Eye Administration: Sterilization, Depyrogenation and Clinical Applications

Long‐Acting Protective Ocular Surface by Instilling Adhesive Dual‐Antiviral Nanoparticles

Contact Info

Product

Resources

About